Target Price | $80.58 |
Price | $48.64 |
Potential |
65.67%
register free of charge
|
Number of Estimates | 25 |
25 Analysts have issued a price target CRISPR Therapeutics AG 2026 .
The average CRISPR Therapeutics AG target price is $80.58.
This is
65.67%
register free of charge
$281.40
478.54%
register free of charge
$32.32
33.55%
register free of charge
|
|
A rating was issued by 34 analysts: 21 Analysts recommend CRISPR Therapeutics AG to buy, 12 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the CRISPR Therapeutics AG stock has an average upside potential 2026 of
65.67%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 37.31 | 48.60 |
89.95% | 30.26% | |
EBITDA Margin | -1,198.90% | -1,044.78% |
2,095.58% | 12.86% | |
Net Margin | -981.64% | -981.32% |
2,272.21% | 0.03% |
28 Analysts have issued a sales forecast CRISPR Therapeutics AG 2025 . The average CRISPR Therapeutics AG sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an CRISPR Therapeutics AG EBITDA forecast 2025. The average CRISPR Therapeutics AG EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
30 CRISPR Therapeutics AG Analysts have issued a net profit forecast 2025. The average CRISPR Therapeutics AG net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -4.34 | -5.52 |
123.71% | 27.19% | |
P/E | negative | |
EV/Sales | 48.26 |
30 Analysts have issued a CRISPR Therapeutics AG forecast for earnings per share. The average CRISPR Therapeutics AG EPS is
This results in the following potential growth metrics and future valuations:
CRISPR Therapeutics AG...
Analyst | Rating | Action | Date |
---|---|---|---|
Clear Street |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Jun 26 2025 |
Needham |
Locked
➜
Locked
|
Locked | Jun 26 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | May 21 2025 |
Analyst Rating | Date |
---|---|
Locked
Clear Street:
Locked
➜
Locked
|
Jun 27 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 27 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Jun 27 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Jun 27 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Jun 26 2025 |
Locked
Needham:
Locked
➜
Locked
|
Jun 26 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
May 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.